M2 Haplotype Test

About Genomic Prediction

Genomic Prediction is a private, commercial-stage company providing sophisticated genetic screening services for the fertility market. Its core innovation is the application of polygenic risk scores (PRS) to embryo selection, moving beyond traditional PGT to assess risk for common diseases like diabetes, heart disease, and cancer. The company's business model is service-based, partnering with fertility clinics and offering tests directly to patients. While generating revenue, it faces significant regulatory, ethical, and market adoption challenges in a competitive landscape.

Therapeutic Areas